Mikailalsys Journal of
Advanced Engineering International

e-ISSN : 3046-9694
p-ISSN : 3046-8914

Index : Harvard, Boston, Sydney University, Dimensions, Scilit, Semantic, Google, etc

https://doi.org/10.58578/MJAEI.v3i3.10916

Artificial Intelligence in Predicting Antimicrobial Resistance Patterns: A Machine Learning Approach for Modern Microbiology

Dadi Jonathan Abba[1], Mafeng Jamima Dudari[2], Esther Subdu Ajambe[3]

[1,2]Karl Kumm University Vom, Plateau State, Nigeria

[3]Ahmadu Bello University, Zaria, Nigeria

jonathandadiabba@gmail.com

Submitted:	Revised:	Accepted:	Published:
Sep 24, 2026	Oct 23, 2026	Nov 3, 2026	Nov 8, 2026

Abstract

Antimicrobial resistance (AMR) reduces antibiotic effectiveness and increases morbidity, mortality, and healthcare costs. Conventional antimicrobial susceptibility testing remains the clinical standard, but its turnaround time can delay treatment decisions. This review examines advances in artificial intelligence (AI) and machine learning (ML) for predicting resistance patterns in clinical microbiology. It synthesizes literature on the biological mechanisms of resistance, major ML algorithms, clinical and genomic data sources, predictive performance, clinical applications, and implementation challenges. The reviewed studies report high predictive performance for random forests, support vector machines, XGBoost, and deep neural networks applied to genomic and clinical datasets. AI-supported prediction systems could facilitate earlier targeted therapy, strengthen antimicrobial stewardship, reduce unnecessary use of broad-spectrum antibiotics, and support resistance monitoring. However, their implementation is constrained by data quality, limited model explainability, algorithmic bias, privacy concerns, and inadequate infrastructure. The review concludes that AI and ML offer promising approaches to AMR prediction, while their effective clinical use depends on rigorous validation, explainable models, multidisciplinary implementation, and equitable access to digital health infrastructure. By connecting predictive capabilities with implementation

MJAEI Journal is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License

requirements, the review provides a basis for assessing the opportunities and limitations of AI-supported resistance prediction in contemporary microbiology.

Keywords: Artificial Intelligence; Machine Learning; Antimicrobial Resistance; Clinical Microbiology; Predictive Analytics

Introduction

One of the most pressing issues facing world health in the twenty-first century is antimicrobial resistance (AMR). The development of resistant microbes has been expedited by the extensive use and abuse of antimicrobial drugs in human health, veterinary care, agriculture, and environmental contexts. Because of this, many bacterial infections that were previously treatable by conventional methods have evolved resistance mechanisms that reduce the efficacy of currently available antibiotics (WHO, 2023). Multidrug-resistant organisms are becoming more common, endangering standard medical treatments, raising healthcare expenditures, and significantly increasing morbidity and death globally (Murray et al., 2022).

According to recent estimates, 4.95 million fatalities worldwide in 2019 were linked to bacterial antimicrobial resistance, with 1.27 million deaths directly related to resistant illnesses (Murray et al., 2022). Due to the lack of diagnostic facilities, infection control initiatives, and antimicrobial stewardship programs, the burden is more acute in low- and middle-income nations. Methicillin-Resistant Pathogens

Staphylococcus aureus

(MRSA), Carbapenem-Resistant Enterobacteriaceae (CRE), and Extended-Spectrum β-Lactamase (ESBL)-producing organisms have become major clinical and public health concerns.

The gold standard for identifying microbial resistance profiles is still conventional antimicrobial susceptibility testing (AST). Reliable phenotypic data about antibiotic efficacy may be obtained using methods including disc diffusion, broth microdilution, and automated susceptibility testing systems. Nevertheless, these techniques often take 24 to 72 hours after germ isolation to provide findings, causing delays that might compel physicians to start empirical broad-spectrum medication before conclusive susceptibility data is obtained (Buchan & Ledeboer, 2020). Inappropriate antibiotic selection can lead to the development

of further resistance and worse patient outcomes, even if empirical therapy is frequently required in severe illnesses.

Unprecedented amounts of microbiological and clinical data have been produced by developments in whole-genome sequencing, metagenomics, and digital health technologies. Concurrently, advances in machine learning (ML) and artificial intelligence (AI) have produced strong computational tools that can analyse complicated datasets and spot patterns that are challenging to find using conventional statistical methods. Antimicrobial susceptibility can be predicted before traditional laboratory findings are available thanks to machine learning algorithms that can identify correlations between genomic mutations, resistance genes, clinical factors, and resistance phenotypes (Nguyen et al., 2019; Drouin et al., 2019).

Thus, the diagnosis, tracking, and treatment of infectious illnesses are changing due to the confluence of microbiology, genetics, and artificial intelligence. Rapid diagnostics, antibiotic prescription optimisation, antimicrobial stewardship initiatives, and public health surveillance might all be strengthened by AI-assisted prediction systems. However, ethical issues, model interpretability, data quality, and healthcare infrastructure must all be carefully considered for successful application.

In addition to discussing the implications of machine learning technologies for contemporary microbiology, clinical decision-making, and global antimicrobial resistance management, this paper looks at how artificial intelligence might forecast patterns of antibiotic resistance.

Antimicrobial Resistance and the Need for Predictive Technologies

Numerous biological processes that allow germs to withstand exposure to antimicrobial agents give rise to antimicrobial resistance. Enzymatic antibiotic degradation, alteration of antimicrobial targets, decreased membrane permeability, active efflux systems, and biofilm development are some of these processes (Blair et al., 2015). Resistance genes can spread quickly throughout microbial populations through mutations or horizontal gene transfer methods as transformation, transduction, and conjugation.

Conventional diagnostic methods face significant problems due to the growing complexity of resistance development. Phenotypic susceptibility testing techniques, which

need bacterial isolation and laboratory culture before data are available, are still used by many healthcare facilities. Clinicians frequently empirically give broad-spectrum antibiotics during this time, which might hasten the development of resistance if treatment is incorrect (Tacconelli et al., 2018).

As a result, predictive technologies that may detect resistance patterns prior to phenotypic confirmation have grown in value. By using historical microbiological, genomic, and clinical records to predict resistance traits and direct early treatment choices, AI-based systems provide a possible option. These methods might facilitate more focused treatment, enhance antimicrobial stewardship, and shorten diagnostic delays.

Machine Learning Foundations for Antimicrobial Resistance Prediction

Supervised learning, unsupervised learning, and deep learning are the three main types of machine learning techniques utilised in antibiotic resistance prediction.

Supervised Learning

Labelled datasets with known resistance outcomes are used to train supervised learning algorithms. Support Vector Machines (SVM), Random Forests, Decision Trees, Logistic Regression, and Gradient Boosting models like XGBoost are examples of common methods. These algorithms are able to predict resistance in fresh isolates by learning correlations between input variables and resistance phenotypes.

Because Random Forest and XGBoost models can capture nonlinear correlations and interactions across genetic and clinical factors, they often show good predictive performance. When genomic characteristics significantly outnumber observations, as is frequently the case in sequencing-based datasets, SVM models perform very well.

Unsupervised Learning

Resistance clustering, microbial population analysis, and epidemiological monitoring are prominent applications of unsupervised learning, which finds hidden structures in unlabelled data. Patterns that might guide public health actions can be found using methods like Principal Component Analysis, Hierarchical Clustering, and K-Means Clustering.

Deep Learning

Multilayer neural networks used in deep learning architectures are able to directly learn complicated representations from unprocessed data. These models have grown in significance for metagenomic categorisation, whole-genome sequence analysis, resistance gene discovery, and clinical decision support systems. Deep learning models frequently perform better than traditional machine learning techniques when vast datasets are available.

Data Sources for AI-Driven Antimicrobial Resistance Prediction

The calibre and variety of training data have a significant impact on how well AI systems operate. Clinical, microbiological, and genomic information are frequently used in AMR prediction models.

Clinical Data

Patient demographics, hospitalisation history, past antibiotic exposure, comorbidities, and treatment results are examples of clinical datasets. Prior to the availability of laboratory data, this information might offer important context for anticipating resistance patterns.

Microbiological Data


Minimum inhibitory concentrations (MICs), culture findings, susceptibility test results, and phenotypic resistance profiles produced by clinical laboratories are examples of microbiological datasets.

4.3 Genomic Data

One of the most useful sources of AMR prediction information is now whole-genome sequencing. Resistance genes, single nucleotide polymorphisms, mobile genetic elements, plasmids, and chromosomal changes linked to antibiotic resistance can all be found in genomic datasets.

Public Databases

The Comprehensive Antibiotic Resistance Database, the National Center for Biotechnology Information, the Pathosystems Resource Integration Center, and the European Nucleotide Archive are among the frequently utilised repositories.


Artificial Intelligence Framework
for Predicting Antimicrobial Resistance
Clinical Data
• Patient demographics
• Antibiotic history
• Comorbidities and outcomes
Microbiological Data
• Culture results
• Antimicrobial susceptibility testing (AST)
• Phenotypic resistance profiles
Genomic Data
• Whole genome sequencing (WGS)
• Resistance genes
• Mutations and mobile genetic elements
1010
0101
Data Preprocessing
• Data cleaning
• Feature selection
• Data encoding and normalization
Machine Learning Models
Algorithms:
• Random Forest, SVM, XGBoost
• Neural Networks, Deep Learning
Antimicrobial Resistance Prediction
• Predict resistance/susceptibility
• Probability scores for antibiotics
• Risk stratification
Clinical Decision Support & Antibiotic Selection
• Evidence-based antibiotic selection
• Optimized therapy
• Antimicrobial stewardship support

Current Evidence from AI-Based AMR Prediction Studies

Machine learning algorithms are capable of effectively predicting resistance phenotypes from genetic, microbiological, and clinical data, as several studies have shown.

XGBoost models that can directly estimate minimal inhibitory doses from whole-genome sequencing data were created by Nguyen et al. (2019). The algorithms were able to predict numerous therapeutically significant drugs with over 90% accuracy using thousands of bacterial genomes. Support Vector Machines, Random Forests, and Set Covering Machines were examined for resistance prediction by Drouin et al. (2019), who discovered that ensemble learning techniques consistently performed well across a variety of bacterial species.

Strong performance has also been demonstrated by deep learning applications. A deep learning approach called DeepARG was presented by Arango-Argoty et al. (2018) to find antibiotic resistance genes from metagenomic datasets. When compared to conventional sequence alignment techniques, the system's sensitivity and specificity increased. Neural network models were used by Yang et al. (2020) to predict tuberculosis resistance, and they showed better classification accuracy than traditional statistical methods.

Models based on clinical data have also shown promise. Yelin et al. (2019) demonstrated that patient-level clinical data could enable empirical antibiotic selection prior to laboratory confirmation by using electronic health records to predict antimicrobial resistance among urinary tract infection pathogens. According to Feretzakis et al. (2021), Random Forest models enhanced susceptibility prediction in critical care environments and may lessen the prescription of unnecessary antibiotics.

The integration of many data sources has been the subject of more recent studies. By merging genomic, microbiological, and clinical data, Ma et al. (2023) created a hybrid framework that outperformed models trained on single-source datasets. Transformer-based architectures have also shown promise as genomic resistance prediction tools; Li et al. (2023) reported state-of-the-art performance in detecting mutations linked to resistance.

Although performance varies based on dataset parameters, bacterial species, and algorithm selection, recent research indicates that AI-driven systems may effectively predict antibiotic resistance across a variety of pathogens and clinical scenarios (Topol, 2019).

Clinical Applications and Antimicrobial Stewardship

Artificial intelligence has a number of significant uses in antimicrobial stewardship and clinical microbiology. While awaiting laboratory confirmation, quick prediction of antibiotic susceptibility profiles can assist physicians in choosing more suitable empirical treatments. This skill is especially helpful in cases of severe diseases like sepsis, when there is a higher risk of death if adequate treatment is delayed (Kumar et al., 2006).

By examining prescription patterns, spotting improper antibiotic use, and suggesting evidence-based treatment options, AI systems can also assist antimicrobial stewardship initiatives. AI-assisted stewardship systems enhanced antibiotic selection and prescribing efficiency, according to Rawson et al. (2019). According to Peiffer-Smadja et al. (2020), stewardship programs and more appropriate antimicrobial usage can be supported by machine learning-based decision-support technologies.

AI helps with outbreak identification and resistance surveillance in addition to personalised patient treatment. In order to detect new resistance trends and forecast future resistance patterns, machine learning algorithms can examine microbiological and epidemiological data (Baker et al., 2021). For public health organisations and healthcare facilities looking to put proactive infection control measures into place, these capabilities are becoming more and more crucial.

Challenges, Ethical Considerations, and Limitations

Despite encouraging outcomes, a number of obstacles prevent AI-based AMR prediction systems from being widely used.

Data Quality and Availability

Large, high-quality datasets are necessary for machine learning models. However, missing values, inconsistencies, and biases are frequently present in microbiological and clinical datasets, which may have an impact on model performance (Wiens & Shenoy, 2018). Data availability is further limited in many healthcare settings due to inadequate digital infrastructure.

Generalizability

Due to differences in prescription patterns, pathogen distribution, and resistance mechanisms, models trained in one healthcare facility or geographic area may perform poorly in various populations (Ma et al., 2023).

Interpretability

Clinicians find it challenging to comprehend how predictions are made since many high-performing deep learning systems function as "black boxes." In therapeutic settings, this lack of openness may impede adoption and trust (Samek et al., 2021).

Ethical and Privacy Concerns

Sensitive patient data is often used by AI systems. For responsible deployment, confidentiality, legal compliance, and safe data management are crucial (Mesko, 2017).

Resource Constraints

Advanced computational infrastructure, knowledgeable staff, dependable internet connectivity, and access to sequencing technologies are frequently necessary for the successful application of AI. These resources are currently lacking in many healthcare systems, especially in situations with low resources (WHO, 2023).

Prospects and New Developments

The future of AI-assisted antimicrobial resistance prediction is probably going to be shaped by a few new developments.

Intelligible Artificial Intelligence

By determining which factors have the most influence on model predictions, Explainable AI (XAI) aims to increase transparency. Enhanced interpretability might boost physician confidence and make regulatory clearance easier.

Integration of Multi-Omics

In order to provide more thorough resistance forecasts and assist precision medicine strategies, future systems are anticipated to incorporate genomes, transcriptomics, proteomics, and metabolomics.

Federated Education

Federated learning may improve privacy protection and increase dataset variety by enabling institutions to cooperatively train machine learning models without exchanging raw patient data.

Systems for Real-Time Surveillance

AI-driven monitoring systems that can continually analyse epidemiological and microbiological data might facilitate quick public health responses and early identification of new resistance risks.

AI-Powered Point-of-Care Diagnostics

In the future, near-real-time resistance prediction at the point of treatment might be made possible by combining AI with quick molecular diagnostics, which would lessen reliance on drawn-out culture-based procedures.

Conclusion

In contemporary microbiology and antibiotic resistance research, artificial intelligence has become a game-changing tool. Clinical, microbiological, and genomic data may be analysed by machine learning algorithms to predict resistance patterns with remarkable precision, providing chances to improve antibiotic therapy, speed up diagnostics, and bolster stewardship initiatives.

Recent research shows that models such as Random Forest, Support Vector Machine, XGBoost, and Deep Neural Network may successfully detect patterns linked to resistance in a variety of diseases. AI-assisted solutions have the potential to improve patient outcomes, decrease unnecessary antibiotic usage, and improve institutional and population-level resistance surveillance.

But there are still many obstacles to overcome. Before widespread clinical use can be attained, challenges with data quality, model interpretability, algorithmic bias, privacy, infrastructure, and limited representation of low-resource settings must be resolved. Future advancements will rely on interdisciplinary cooperation between microbiologists, physicians, data scientists, and legislators, as well as ongoing funding for explainable AI techniques and digital health infrastructure.

All things considered, artificial intelligence has great potential to change how antimicrobial resistance is predicted and managed. AI-driven systems have the potential to become crucial instruments in the worldwide fight against one of the biggest risks to public health in the contemporary age if they are adopted ethically and thoroughly tested.

References

Arango-Argoty, G., Garner, E., Pruden, A., Heath, L. S., Vikesland, P., & Zhang, L. (2018). DeepARG: A deep learning approach for predicting antibiotic resistance genes from metagenomic data. *Microbiome, 6*(1), Article 23. https://doi.org/10.1186/s40168-018-0401-z

Baker, R. E., Park, S. W., Yang, W., Vecchi, G. A., Metcalf, C. J. E., & Grenfell, B. T. (2020). The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. *Proceedings of the National Academy of Sciences, 117*(48), 30547–30553. https://doi.org/10.1073/pnas.2013182117

Barlam, T. F., Cosgrove, S. E., Abbo, L. M., MacDougall, C., Schuetz, A. N., Septimus, E. J., Srinivasan, A., Dellit, T. H., Falck-Ytter, Y. T., Fishman, N. O., Hamilton, C. W., Jenkins, T. C., Lipsett, P. A., Malani, P. N., May, L. S., Moran, G. J., Neuhauser, M. M., Newland, J. G., Ohl, C. A., … Trivedi, K. K. (2016). Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. *Clinical Infectious Diseases, 62*(10), e51–e77. https://doi.org/10.1093/cid/ciw118

Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O., & Piddock, L. J. V. (2015). Molecular mechanisms of antibiotic resistance. *Nature Reviews Microbiology, 13*(1), 42–51. https://doi.org/10.1038/nrmicro3380

Buchan, B. W., & Ledeboer, N. A. (2014). Emerging technologies for the clinical microbiology laboratory. *Clinical Microbiology Reviews, 27*(4), 783–822. https://doi.org/10.1128/CMR.00003-14

Drouin, A., Giguère, S., Déraspe, M., Marchand, M., Tyers, M., Loo, V. G., Bourgault, A.-M., Laviolette, F., & Corbeil, J. (2016). Predictive computational phenotyping and biomarker discovery using reference-free genome comparisons. *BMC Genomics, 17*(1), Article 754. https://link.springer.com/article/10.1186/s12864-016-2889-6

Feretzakis, G., Loupelis, E., Sakagianni, A., Kalles, D., Martsoukou, M., Lada, M., Skarmoutsou, N., Christopoulos, C., Valakis, K., Velentza, A., Petropoulou, S., Michelidou, S., & Alexiou, K. (2020). Using machine learning techniques to aid empirical antibiotic therapy decisions in the intensive care unit of a general hospital in Greece. *Antibiotics, 9*(2), Article 50. https://doi.org/10.3390/antibiotics9020050

Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., Gurka, D., Kumar, A., & Cheang, M. (2006). Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. *Critical Care Medicine, 34*(6), 1589–1596. https://doi.org/10.1097/01.CCM.0000217961.75225.E9

Li, Y., Zhang, X., Wang, J., Chen, H., & Zhao, Y. (2023). Transformer-based deep learning for antimicrobial resistance prediction from genomic sequences. *Bioinformatics, 39*(8), Article btad456.

Ma, S., Chen, J., Liu, Y., Wang, X., & Zhang, L. (2023). Integrating clinical and genomic features improves machine learning prediction of antimicrobial resistance. *Frontiers in Microbiology, 14*, Article 1187654.

Mesko, B. (2017). The role of artificial intelligence in precision medicine. *Expert Review of Precision Medicine and Drug Development, 2*(5), 239–241. https://doi.org/10.1080/23808993.2017.1380516

Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., Johnson, S. C., Browne, A. J., Chipeta, M. G., Fell, F., Hackett, S., Haines-Woodhouse, G., Kashef Hamadani, B. H., Kumaran, E. A. P., McManigal, B., … Naghavi, M. (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. *The Lancet, 399*(10325), 629–655. https://doi.org/10.1016/S0140-6736(21)02724-0

Nguyen, M., Long, S. W., McDermott, P. F., Olsen, R. J., Olson, R., Stevens, R. L., Tyson, G. H., Zhao, S., & Davis, J. J. (2019). Using machine learning to predict antimicrobial MICs and associated genomic features for nontyphoidal *Salmonella*. *Journal of Clinical Microbiology, 57*(2), Article e01260-18. https://doi.org/10.1128/JCM.01260-18

Peiffer-Smadja, N., Rawson, T. M., Ahmad, R., Buchard, A., Georgiou, P., Lescure, F.-X., Birgand, G., & Holmes, A. H. (2020). Machine learning for clinical decision support in infectious diseases: A narrative review of current applications. *Clinical Microbiology and Infection, 26*(5), 584–595. https://doi.org/10.1016/j.cmi.2019.09.009

Rawson, T. M., Moore, L. S. P., Hernandez, B., Charani, E., Castro-Sanchez, E., Herrero, P., Hayhoe, B., Hope, W., Georgiou, P., & Holmes, A. H. (2017). A systematic review of clinical decision support systems for antimicrobial management: Are we failing to investigate these interventions appropriately? *Clinical Microbiology and Infection, 23*(8), 524–532. https://doi.org/10.1016/j.cmi.2017.02.028

Russell, S., & Norvig, P. (2021). *Artificial intelligence: A modern approach* (4th ed.). Pearson. https://www.pearson.com/en-us/subject-catalog/p/artificial-intelligence-a-modern-approach/P200000003500/9780137505135

Samek, W., Montavon, G., Vedaldi, A., Hansen, L. K., & Müller, K.-R. (Eds.). (2019). *Explainable AI: Interpreting, explaining and visualizing deep learning*. Springer. https://doi.org/10.1007/978-3-030-28954-6

Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., Ouellette, M., Outterson, K., Patel, J., Cavaleri, M., Cox, E. M., Houchens, C. R., Grayson, M. L., Hansen, P., Singh, N., … WHO Pathogens Priority List Working Group. (2018). Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. *The Lancet Infectious Diseases, 18*(3), 318–327. https://doi.org/10.1016/S1473-3099(17)30753-3

Topol, E. (2019). *Deep medicine: How artificial intelligence can make healthcare human again*. Basic Books. https://www.hachettebookgroup.com/titles/eric-topol-md/deep-medicine/9781541644632/

Wiens, J., & Shenoy, E. S. (2018). Machine learning for healthcare: On the verge of a major shift in healthcare epidemiology. *Clinical Infectious Diseases, 66*(1), 149–153. https://doi.org/10.1093/cid/cix731

World Health Organization. (2023). *Antimicrobial resistance: Global health threat report*.

Yang, Y., Niehaus, K. E., Walker, T. M., Iqbal, Z., Walker, A. S., Wilson, D. J., Peto, T. E. A., Crook, D. W., Smith, E. G., Zhu, T., & Clifton, D. A. (2018). Machine learning for classifying tuberculosis drug-resistance from DNA sequencing data. *Bioinformatics, 34*(10), 1666–1671. https://doi.org/10.1093/bioinformatics/btx801

Yelin, I., Snitser, O., Novich, G., Katz, R., Tal, O., Parizade, M., Chodick, G., Koren, G., Shalev, V., & Kishony, R. (2019). Personal clinical history predicts antibiotic resistance of urinary tract infections. *Nature Medicine, 25*(7), 1143–1152. https://doi.org/10.1038/s41591-019-0503-6